Eicosapentaenoic acid (EPA) decreases the all-cause mortality in hemodialysis patients

Internal Medicine

Volumn 54, Issue 24, 2015, Pages 3133-3137

  Inoue, Tomoko ^a   Okano, Kazuhiro ^a   Tsuruta, Yuki ^b   Tsuruta, Yukio ^b   Tsuchiya, Ken ^a   Akiba, Takashi ^a   Nitta, Kosaku ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b Tsuruta Clinic   (Japan)

Author keywords

Dialysis; Eicosapentaenoic acid; Fish oil; Mortality

Indexed keywords

ICOSAPENTAENOIC ACID;

ADULT; ARTICLE; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; OBSERVATIONAL STUDY; PROPENSITY SCORE; SURVIVAL RATE; ADVERSE EFFECTS; ATHEROSCLEROSIS; CAUSE OF DEATH; KIDNEY FAILURE, CHRONIC; PATHOPHYSIOLOGY; PROGNOSIS; RENAL REPLACEMENT THERAPY; RISK;

ATHEROSCLEROSIS; CAUSE OF DEATH; EICOSAPENTAENOIC ACID; FEMALE; HUMANS; KIDNEY FAILURE, CHRONIC; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROGNOSIS; RENAL DIALYSIS; RISK;

EID: 84949771703     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.54.4931     Document Type: Article

References (25)

1. US Renal Data System. USRDS 1998 Annual Data Report. Am J Kidney Dis 32: S69-S80, 1998.
2. Kasiske BL. Hyperlipidemia in patients with chronic kidney disease. Am J Kidney Dis 32: S142-S156, 1998.
3. Shoji T, Nishizawa Y, Kawagishi T, et al. Intermediate-density lipoprotein as an independent risk factor for aortic atherosclerosis in hemodialysis patients. J Am Soc Nephrol 9: 1277-1284, 1998.
4. Ikizler TA, Morrow JD, Roberts LJ, et al. Plasma F2-isoprostane levels are elevated in chronic hemodialysis patients. Clin Nephrol 58: 190-197, 2002.
5. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vitro peroxidation of LDL in dialysis patients. J Am Soc Nephrol 10: 2177-2184, 1999.
6. Hu ML, Louie S, Cross CE. Antioxidant protection against hypochlorous acid in human plasma. J Lab Clin Med 121: 257-262, 1993.
7. Harris WS. Fish oil and plasma lipid and lipoprotein metabolism in humans: a critical review. J Lipid Res 30: 785-807, 1989.
8. Mozaffarian D, Rimm EB. Fish intake, contaminants, and human health: evaluating the risks and the benefits. JAMA 296: 1885-1899, 2006.
9. von Schacky C. n-3 PUFA in CVD: influence of cytokine polymorphism. Proc Nutr Soc 66: 166-170, 2007.
10. Harris WS, Miller M, Tighe AP, Davidson MH, Schaefer EJ. Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives. Atherosclerosis 197: 12-24, 2008.
11. Takahashi M, Tsuboyama-Kasaoka N, Nakatani T, et al. Fish oil feeding alters liver gene expression to defend against PPAR alpha activation and ROS production. Am J Physiol Gastrointest Liver Physiol 282: G338-G348, 2002.
12. Calder PC. Polyunsaturated fatty acids, inflammation, and immunity. Lipids 36: 1007-1024, 2001.
13. Iso H, Kobayashi M, Ishihara J, et al. Intake of fish and n-3 fatty acids and risk of coronary heart disease among Japanese: the Japan Public Health Center-based (JPHC) Study Cohort I. Circulation 113: 195-202, 2006.
14. Albert CM, Campos H, Stampfer MJ, et al. Blood levels of longchain n-3 fatty acids and the risk of sudden death. N Engl J Med 346: 1113-1118, 2002.
15. Yokoyama M, Origasa H, Matsuzaki M, et al. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomized open-label, blinded endpoint analysis. Lancet 369: 1090-1098, 2007.
16. Kutner NG, Clow PW, Zhang R, Aviles X. Association of fish intake and survival in a cohort of incident dialysis patients. Am J Kidney Dis 39: 1018-1024, 2002.
17. Svensson M, Schmidt EB, Jørgensen KA, Christensen JH; OPACH Study Group. N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial. Clin J Am Soc Nephrol 1: 780-786, 2006.
18. Kanai S, Uto K, Honda K, Hagiwara N, Oda H. Eicosapentaenoic acid reduces warfarin-induced arterial calcification in rats. Atherosclerosis 215: 43-51, 2011.
19. Thies F, Garry JM, Yaqoob P, et al. Association of n-3 polyunsaturated fatty acids with stability of atherosclerotic plaques: a randomized controlled trial. Lancet 361: 477-485, 2003.
20. Hamazaki K, Terashima Y, Itomura M, et al. Docosahexaenoic acid is an independent predictor of all-cause mortality in hemodialysis patients. Am J Nephrol 33: 105-110, 2011.
21. Goldberg AP, Applebaum-Bowden DM, Bierman EL, et al. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N Engl J Med 301: 1073-1076, 1979.
22. Kijima Y, Sasaoka T, Kanayama M, Kubota S. Untoward effects of clofibrate in hemodialyzed patients. N Engl J Med 296: 515, 1977.
23. Palmer SC, Craiq JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and metaanalysis. Ann Intern Med 157: 263-275, 2012.
24. Olyaei A, Greer E, Delos Santos R, Rueda J. The efficacy and safety of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors in chronic kidney disease, dialysis, and transplant patients. Clin J Am Soc Nephrol 6: 664-678, 2011.
25. Nakamura T, Azuma A, Kuribayashi T, Sugihara H, Okuda S, Nakagawa M. Serum fatty acid levels, dietary style and coronary heart disease in three neighbouring areas in Japan: the Kumihama study. Br J Nutr 89: 267-272, 2003.